

web: <https://covidcirrhosis.web.unc.edu/>
email: covid.cirrhosis@unc.edu
twitter: @SecureCirrhosis

web: <https://covid-hep.net>
email: info@covid-hep.net
twitter: @COVIDHep

Combined update – 25 Aug 2020

We welcome you to this combined update from our two collaborating international registries: **SECURE-Cirrhosis** and **EASL supported COVID-Hep** collating clinical details of patients with chronic liver disease who develop COVID-19. *Please note that our registries contain predominantly hospitalised patients and are subject to reporting biases.*

Total cohort (n = 1102 from 1269 submissions)

Submissions from 35 countries



Characteristics

929 (84%) hospitalised
691 (63%) men
Median age 58 years (IQR 47-67)
227 (21%) taking immunosuppressant drugs

Output

Chronic liver disease, JHep: bit.ly/3bYxUy6
★ Transplant full paper out in Lancet G&H 28th August
★ Presentation at EASL ILC 29th August 16:15 CET

Chronic liver disease, non-cirrhotic (n = 424)

Major outcomes

Hospitalised	346	82%
Intensive care admission	70	17%
Invasive ventilation	64	15%
Death	29	7%

Cirrhosis (n = 508)

Major aetiologies

Alcohol	148	29%
Non-alcoholic steatohepatitis	104	20%
Hepatitis C	56	11%
Autoimmune hepatitis	36	7%
Hepatitis B	35	7%
Alcohol & HCV	27	5%

Decompensation

Any	241	47%
New or worse ascites	137	27%
New or worse encephalopathy	131	26%
Variceal haemorrhage	35	7%

Major outcomes

Hospitalised	445	88%
Intensive care admission	141	27%
Invasive ventilation	95	19%
Death	158	31%

Liver transplant (n = 170)

Major outcomes

Hospitalised	137	81%
Intensive care admission	48	28%
Invasive ventilation	32	19%
Death	31	18%

We look forward to providing more updates in future and soon hope to publish more definitive analyses of both our transplant and chronic liver disease cohorts. We would like to thank all contributors to both registries.